Sudarshan Pharma Industries Ltd Financials
Company Logo

Sudarshan Pharma Industries Ltd Financial Statement

Sudarshan Pharma Industries Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

No Data Available

Sudarshan Pharma Industries Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual465.56
Operating Expenses Annual442.96
Operating Profit Annual25.36
Interest Annual9.03
Depreciation1.23
Net Profit Annual11.36
Tax Annual3.74

Sudarshan Pharma Industries Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning11.71
Cash Flow from Operations7.95
Cash Flow from Investing-7.35
Cash Flow from Financing-12.18
Cash Flow at the End0.13

Sudarshan Pharma Industries Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)5.45
PBIT Margin (%)5.18
PBT Margin (%)4.61
Net PROFIT Margin (%)2.44
Return On Networth / Equity (%)10.69
Return On Networth /Employed (%)13.64
Return On Assets (%)6.42
Total Debt / Equity (X)0.66
Asset Turnover Ratio (%)2.63

Sudarshan Pharma Industries Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual20.57
Total Current Assets Annual245.20
Non Current Assets Annual39.64
Total Shareholders Funds Annual111.62
Total Assets Annual284.84

Sudarshan Pharma Industries Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Nov 5, 2024, Sudarshan Pharma Industries Ltd has a market capitalization of 178.35 Cr. Value Research classifies it as a Micro-Cap company.
No, Sudarshan Pharma Industries Ltd is not debt-free with a debt-to-equity ratio of 0.96.
In FY 2023 , Sudarshan Pharma Industries Ltd recorded a total revenue of approximately 465.56 Cr marking a significant milestone in the company's financial performance.
Sudarshan Pharma Industries Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately Infinity% and 0.1% annually, respectively..
Sudarshan Pharma Industries Ltd's current PE ratio is 15.70.
Sudarshan Pharma Industries Ltd's ROCE averaged 13.2% from the FY ending March 2022 to 2024, with a median of 11.0%. It peaked at 17.4% in March 2022, reflecting strong capital efficiency over the period..
Sudarshan Pharma Industries Ltd's latest EBIT is Rs. 24.13 Cr, surpassing the average EBIT of Rs. 16.52 Cr over the 5 years..